Poxel is a cutting-edge laboratory at the forefront of developing innovative treatments for various diseases and conditions. With a focus on metabolic disorders, Poxel is revolutionizing the field of medicine, offering hope for millions of individuals worldwide.

Metabolic disorders, such as type 2 diabetes, non-alcoholic steatohepatitis (NASH), and rare genetic disorders, pose significant challenges to patients and healthcare providers alike. Traditional treatment options often fall short in addressing the underlying causes of these conditions, leaving patients with limited relief and a diminished quality of life.

Poxel breaks this mold by championing a unique approach to drug development. By targeting the root causes of metabolic disorders rather than merely managing symptoms, Poxel aims to provide long-lasting and transformative solutions. Through innovative science and an unwavering commitment to patient well-being, Poxel is reshaping the future of healthcare.

One area of focus for Poxel is type 2 diabetes, a chronic condition affecting millions worldwide. Traditional treatment options for diabetes often rely on insulin injections or oral medications that primarily target glucose levels. Poxel, however, has developed a first-in-class therapeutic approach targeting mitochondrial bioenergetics, a cellular process crucial in glucose metabolism. Their investigative drug, Imeglimin, aims to improve mitochondrial function, resulting in enhanced glucose-stimulated insulin secretion and improved blood sugar control. Clinical trials have shown promising results, positioning Poxel as a possible game-changer in the diabetes landscape.

In addition to type 2 diabetes, Poxel is also dedicated to addressing the unmet medical needs in NASH, a progressive liver disease with no approved therapies to date. NASH is often associated with obesity and insulin resistance, making it a natural fit within Poxel’s expertise. The laboratory’s lead candidate, PXL770, targets the AMP-activated protein kinase (AMPK) pathway, which plays a crucial role in metabolic regulation. By modulating this pathway, PXL770 aims to improve insulin sensitivity, reduce liver inflammation, and ultimately halt disease progression. Early clinical data has shown encouraging results, positioning Poxel as a frontrunner in NASH treatment research.

Poxel’s commitment to developing innovative treatments extends beyond commonly recognized metabolic disorders. The laboratory is also actively involved in advancing therapeutic options for rare genetic disorders, such as adrenoleukodystrophy (ALD) and X-linked adrenoleukodystrophy (X-ALD). These disorders, often affecting children, result from a mutation in the ABCD1 gene, leading to the accumulation of toxic fatty acids. Poxel’s research focuses on developing a selective modulator of the peroxisome proliferator-activated receptor delta (PPARδ), aiming to restore fatty acid homeostasis and alleviate the devastating effects of these rare diseases. By addressing the underlying genetic mutations, Poxel aims to provide much-needed hope for affected individuals and their families.

With their groundbreaking research and commitment to patient-centric innovation, Poxel is revolutionizing the field of metabolic disorders. By addressing the root causes of diseases rather than merely managing symptoms, the laboratory offers a glimmer of hope for individuals burdened by these conditions. Through their dedication to scientific excellence and unwavering pursuit of advancements, Poxel is poised to transform the lives of millions, ushering in a new era of innovative treatments and improved patient outcomes.

Quest'articolo è stato scritto a titolo esclusivamente informativo e di divulgazione. Per esso non è possibile garantire che sia esente da errori o inesattezze, per cui l’amministratore di questo Sito non assume alcuna responsabilità come indicato nelle note legali pubblicate in Termini e Condizioni
Quanto è stato utile questo articolo?
0Vota per primo questo articolo!